Global Heart Failure Drugs Market Growth 2025-2031

January 2025 | 108 pages | ID: G5D8784F224EEN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Heart Failure Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Heart failure occurs when your heart muscle doesn't pump blood as well as it should.

The market is concentrated as Novartis, Pfizer, AstraZeneca , Hikma, Teva etc. Turkey is the largest consumption place in the Turkey and Middle East & Africa market, with a consumption market share nearly 21%.

LP Information, Inc. (LPI) ' newest research report, the “Heart Failure Drugs Industry Forecast” looks at past sales and reviews total world Heart Failure Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Heart Failure Drugs sales for 2025 through 2031. With Heart Failure Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Heart Failure Drugs industry.

This Insight Report provides a comprehensive analysis of the global Heart Failure Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Heart Failure Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Heart Failure Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Heart Failure Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Heart Failure Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Heart Failure Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• ACEI
• Angiotensin II Receptor Blockers
• ARNIs
• Beta Blockers
• Aldosterone Antagonists
• Diuretics

Segmentation by Application:

• Reduced Ejection Fraction
• Preserved Ejection Fraction

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Novartis
• Pfizer
• AstraZeneca
• Hikma
• Teva
• Cipla
• Merck & Co.
• Amgen
• Roche
• Sun Pharma
• Mylan

Key Questions Addressed in this Report

What is the 10-year outlook for the global Heart Failure Drugs market?

What factors are driving Heart Failure Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Heart Failure Drugs market opportunities vary by end market size?

How does Heart Failure Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Heart Failure Drugs Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Heart Failure Drugs by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Heart Failure Drugs by Country/Region, 2020, 2024 & 2031
2.2 Heart Failure Drugs Segment by Type
  2.2.1 ACEI
  2.2.2 Angiotensin II Receptor Blockers
  2.2.3 ARNIs
  2.2.4 Beta Blockers
  2.2.5 Aldosterone Antagonists
  2.2.6 Diuretics
2.3 Heart Failure Drugs Sales by Type
  2.3.1 Global Heart Failure Drugs Sales Market Share by Type (2020-2025)
  2.3.2 Global Heart Failure Drugs Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Heart Failure Drugs Sale Price by Type (2020-2025)
2.4 Heart Failure Drugs Segment by Application
  2.4.1 Reduced Ejection Fraction
  2.4.2 Preserved Ejection Fraction
2.5 Heart Failure Drugs Sales by Application
  2.5.1 Global Heart Failure Drugs Sale Market Share by Application (2020-2025)
  2.5.2 Global Heart Failure Drugs Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Heart Failure Drugs Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Heart Failure Drugs Breakdown Data by Company
  3.1.1 Global Heart Failure Drugs Annual Sales by Company (2020-2025)
  3.1.2 Global Heart Failure Drugs Sales Market Share by Company (2020-2025)
3.2 Global Heart Failure Drugs Annual Revenue by Company (2020-2025)
  3.2.1 Global Heart Failure Drugs Revenue by Company (2020-2025)
  3.2.2 Global Heart Failure Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Heart Failure Drugs Sale Price by Company
3.4 Key Manufacturers Heart Failure Drugs Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Heart Failure Drugs Product Location Distribution
  3.4.2 Players Heart Failure Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR HEART FAILURE DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Heart Failure Drugs Market Size by Geographic Region (2020-2025)
  4.1.1 Global Heart Failure Drugs Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Heart Failure Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Heart Failure Drugs Market Size by Country/Region (2020-2025)
  4.2.1 Global Heart Failure Drugs Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Heart Failure Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Heart Failure Drugs Sales Growth
4.4 APAC Heart Failure Drugs Sales Growth
4.5 Europe Heart Failure Drugs Sales Growth
4.6 Middle East & Africa Heart Failure Drugs Sales Growth

5 AMERICAS

5.1 Americas Heart Failure Drugs Sales by Country
  5.1.1 Americas Heart Failure Drugs Sales by Country (2020-2025)
  5.1.2 Americas Heart Failure Drugs Revenue by Country (2020-2025)
5.2 Americas Heart Failure Drugs Sales by Type (2020-2025)
5.3 Americas Heart Failure Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Heart Failure Drugs Sales by Region
  6.1.1 APAC Heart Failure Drugs Sales by Region (2020-2025)
  6.1.2 APAC Heart Failure Drugs Revenue by Region (2020-2025)
6.2 APAC Heart Failure Drugs Sales by Type (2020-2025)
6.3 APAC Heart Failure Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Heart Failure Drugs by Country
  7.1.1 Europe Heart Failure Drugs Sales by Country (2020-2025)
  7.1.2 Europe Heart Failure Drugs Revenue by Country (2020-2025)
7.2 Europe Heart Failure Drugs Sales by Type (2020-2025)
7.3 Europe Heart Failure Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Heart Failure Drugs by Country
  8.1.1 Middle East & Africa Heart Failure Drugs Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Heart Failure Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Heart Failure Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Heart Failure Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Heart Failure Drugs
10.3 Manufacturing Process Analysis of Heart Failure Drugs
10.4 Industry Chain Structure of Heart Failure Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Heart Failure Drugs Distributors
11.3 Heart Failure Drugs Customer

12 WORLD FORECAST REVIEW FOR HEART FAILURE DRUGS BY GEOGRAPHIC REGION

12.1 Global Heart Failure Drugs Market Size Forecast by Region
  12.1.1 Global Heart Failure Drugs Forecast by Region (2026-2031)
  12.1.2 Global Heart Failure Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Heart Failure Drugs Forecast by Type (2026-2031)
12.7 Global Heart Failure Drugs Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Novartis
  13.1.1 Novartis Company Information
  13.1.2 Novartis Heart Failure Drugs Product Portfolios and Specifications
  13.1.3 Novartis Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Novartis Main Business Overview
  13.1.5 Novartis Latest Developments
13.2 Pfizer
  13.2.1 Pfizer Company Information
  13.2.2 Pfizer Heart Failure Drugs Product Portfolios and Specifications
  13.2.3 Pfizer Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Pfizer Main Business Overview
  13.2.5 Pfizer Latest Developments
13.3 AstraZeneca
  13.3.1 AstraZeneca Company Information
  13.3.2 AstraZeneca Heart Failure Drugs Product Portfolios and Specifications
  13.3.3 AstraZeneca Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 AstraZeneca Main Business Overview
  13.3.5 AstraZeneca Latest Developments
13.4 Hikma
  13.4.1 Hikma Company Information
  13.4.2 Hikma Heart Failure Drugs Product Portfolios and Specifications
  13.4.3 Hikma Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Hikma Main Business Overview
  13.4.5 Hikma Latest Developments
13.5 Teva
  13.5.1 Teva Company Information
  13.5.2 Teva Heart Failure Drugs Product Portfolios and Specifications
  13.5.3 Teva Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Teva Main Business Overview
  13.5.5 Teva Latest Developments
13.6 Cipla
  13.6.1 Cipla Company Information
  13.6.2 Cipla Heart Failure Drugs Product Portfolios and Specifications
  13.6.3 Cipla Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Cipla Main Business Overview
  13.6.5 Cipla Latest Developments
13.7 Merck & Co.
  13.7.1 Merck & Co. Company Information
  13.7.2 Merck & Co. Heart Failure Drugs Product Portfolios and Specifications
  13.7.3 Merck & Co. Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Merck & Co. Main Business Overview
  13.7.5 Merck & Co. Latest Developments
13.8 Amgen
  13.8.1 Amgen Company Information
  13.8.2 Amgen Heart Failure Drugs Product Portfolios and Specifications
  13.8.3 Amgen Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Amgen Main Business Overview
  13.8.5 Amgen Latest Developments
13.9 Roche
  13.9.1 Roche Company Information
  13.9.2 Roche Heart Failure Drugs Product Portfolios and Specifications
  13.9.3 Roche Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.9.4 Roche Main Business Overview
  13.9.5 Roche Latest Developments
13.10 Sun Pharma
  13.10.1 Sun Pharma Company Information
  13.10.2 Sun Pharma Heart Failure Drugs Product Portfolios and Specifications
  13.10.3 Sun Pharma Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.10.4 Sun Pharma Main Business Overview
  13.10.5 Sun Pharma Latest Developments
13.11 Mylan
  13.11.1 Mylan Company Information
  13.11.2 Mylan Heart Failure Drugs Product Portfolios and Specifications
  13.11.3 Mylan Heart Failure Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.11.4 Mylan Main Business Overview
  13.11.5 Mylan Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION


LIST OFTABLES

Table 1. HeartFailure Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. HeartFailure Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of ACEI
Table 4. Major Players of Angiotensin II Receptor Blockers
Table 5. Major Players of ARNIs
Table 6. Major Players of Beta Blockers
Table 7. Major Players of Aldosterone Antagonists
Table 8. Major Players of Diuretics
Table 9. Global HeartFailure Drugs Sales byType (2020-2025) & (MT)
Table 10. Global HeartFailure Drugs Sales Market Share byType (2020-2025)
Table 11. Global HeartFailure Drugs Revenue byType (2020-2025) & ($ million)
Table 12. Global HeartFailure Drugs Revenue Market Share byType (2020-2025)
Table 13. Global HeartFailure Drugs Sale Price byType (2020-2025) & (USD/MT)
Table 14. Global HeartFailure Drugs Sale by Application (2020-2025) & (MT)
Table 15. Global HeartFailure Drugs Sale Market Share by Application (2020-2025)
Table 16. Global HeartFailure Drugs Revenue by Application (2020-2025) & ($ million)
Table 17. Global HeartFailure Drugs Revenue Market Share by Application (2020-2025)
Table 18. Global HeartFailure Drugs Sale Price by Application (2020-2025) & (USD/MT)
Table 19. Global HeartFailure Drugs Sales by Company (2020-2025) & (MT)
Table 20. Global HeartFailure Drugs Sales Market Share by Company (2020-2025)
Table 21. Global HeartFailure Drugs Revenue by Company (2020-2025) & ($ millions)
Table 22. Global HeartFailure Drugs Revenue Market Share by Company (2020-2025)
Table 23. Global HeartFailure Drugs Sale Price by Company (2020-2025) & (USD/MT)
Table 24. Key Manufacturers HeartFailure Drugs Producing Area Distribution and Sales Area
Table 25. Players HeartFailure Drugs Products Offered
Table 26. HeartFailure Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global HeartFailure Drugs Sales by Geographic Region (2020-2025) & (MT)
Table 30. Global HeartFailure Drugs Sales Market Share Geographic Region (2020-2025)
Table 31. Global HeartFailure Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 32. Global HeartFailure Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 33. Global HeartFailure Drugs Sales by Country/Region (2020-2025) & (MT)
Table 34. Global HeartFailure Drugs Sales Market Share by Country/Region (2020-2025)
Table 35. Global HeartFailure Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 36. Global HeartFailure Drugs Revenue Market Share by Country/Region (2020-2025)
Table 37. Americas HeartFailure Drugs Sales by Country (2020-2025) & (MT)
Table 38. Americas HeartFailure Drugs Sales Market Share by Country (2020-2025)
Table 39. Americas HeartFailure Drugs Revenue by Country (2020-2025) & ($ millions)
Table 40. Americas HeartFailure Drugs Sales byType (2020-2025) & (MT)
Table 41. Americas HeartFailure Drugs Sales by Application (2020-2025) & (MT)
Table 42. APAC HeartFailure Drugs Sales by Region (2020-2025) & (MT)
Table 43. APAC HeartFailure Drugs Sales Market Share by Region (2020-2025)
Table 44. APAC HeartFailure Drugs Revenue by Region (2020-2025) & ($ millions)
Table 45. APAC HeartFailure Drugs Sales byType (2020-2025) & (MT)
Table 46. APAC HeartFailure Drugs Sales by Application (2020-2025) & (MT)
Table 47. Europe HeartFailure Drugs Sales by Country (2020-2025) & (MT)
Table 48. Europe HeartFailure Drugs Revenue by Country (2020-2025) & ($ millions)
Table 49. Europe HeartFailure Drugs Sales byType (2020-2025) & (MT)
Table 50. Europe HeartFailure Drugs Sales by Application (2020-2025) & (MT)
Table 51. Middle East & Africa HeartFailure Drugs Sales by Country (2020-2025) & (MT)
Table 52. Middle East & Africa HeartFailure Drugs Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa HeartFailure Drugs Sales byType (2020-2025) & (MT)
Table 54. Middle East & Africa HeartFailure Drugs Sales by Application (2020-2025) & (MT)
Table 55. Key Market Drivers & Growth Opportunities of HeartFailure Drugs
Table 56. Key Market Challenges & Risks of HeartFailure Drugs
Table 57. Key IndustryTrends of HeartFailure Drugs
Table 58. HeartFailure Drugs Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. HeartFailure Drugs Distributors List
Table 61. HeartFailure Drugs Customer List
Table 62. Global HeartFailure Drugs SalesForecast by Region (2026-2031) & (MT)
Table 63. Global HeartFailure Drugs RevenueForecast by Region (2026-2031) & ($ millions)
Table 64. Americas HeartFailure Drugs SalesForecast by Country (2026-2031) & (MT)
Table 65. Americas HeartFailure Drugs Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 66. APAC HeartFailure Drugs SalesForecast by Region (2026-2031) & (MT)
Table 67. APAC HeartFailure Drugs Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 68. Europe HeartFailure Drugs SalesForecast by Country (2026-2031) & (MT)
Table 69. Europe HeartFailure Drugs RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Middle East & Africa HeartFailure Drugs SalesForecast by Country (2026-2031) & (MT)
Table 71. Middle East & Africa HeartFailure Drugs RevenueForecast by Country (2026-2031) & ($ millions)
Table 72. Global HeartFailure Drugs SalesForecast byType (2026-2031) & (MT)
Table 73. Global HeartFailure Drugs RevenueForecast byType (2026-2031) & ($ millions)
Table 74. Global HeartFailure Drugs SalesForecast by Application (2026-2031) & (MT)
Table 75. Global HeartFailure Drugs RevenueForecast by Application (2026-2031) & ($ millions)
Table 76. Novartis Basic Information, HeartFailure Drugs Manufacturing Base, Sales Area and Its Competitors
Table 77. Novartis HeartFailure Drugs Product Portfolios and Specifications
Table 78. Novartis HeartFailure Drugs Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. Pfizer Basic Information, HeartFailure Drugs Manufacturing Base, Sales Area and Its Competitors
Table 82. Pfizer HeartFailure Drugs Product Portfolios and Specifications
Table 83. Pfizer HeartFailure Drugs Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 84. Pfizer Main Business
Table 85. Pfizer Latest Developments
Table 86. AstraZeneca Basic Information, HeartFailure Drugs Manufacturing Base, Sales Area and Its Competitors
Table 87. AstraZeneca HeartFailure Drugs Product Portfolios and Specifications
Table 88. AstraZeneca HeartFailure Drugs Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 89. AstraZeneca Main Business
Table 90. AstraZeneca Latest Developments
Table 91. Hikma Basic Information, HeartFailure Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Hikma HeartFailure Drugs Product Portfolios and Specifications
Table 93. Hikma HeartFailure Drugs Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 94. Hikma Main Business
Table 95. Hikma Latest Developments
Table 96.Teva Basic Information, HeartFailure Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97.Teva HeartFailure Drugs Product Portfolios and Specifications
Table 98.Teva HeartFailure Drugs Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 99.Teva Main Business
Table 100.Teva Latest Developments
Table 101. Cipla Basic Information, HeartFailure Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. Cipla HeartFailure Drugs Product Portfolios and Specifications
Table 103. Cipla HeartFailure Drugs Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 104. Cipla Main Business
Table 105. Cipla Latest Developments
Table 106. Merck & Co. Basic Information, HeartFailure Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. Merck & Co. HeartFailure Drugs Product Portfolios and Specifications
Table 108. Merck & Co. HeartFailure Drugs Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 109. Merck & Co. Main Business
Table 110. Merck & Co. Latest Developments
Table 111. Amgen Basic Information, HeartFailure Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. Amgen HeartFailure Drugs Product Portfolios and Specifications
Table 113. Amgen HeartFailure Drugs Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 114. Amgen Main Business
Table 115. Amgen Latest Developments
Table 116. Roche Basic Information, HeartFailure Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. Roche HeartFailure Drugs Product Portfolios and Specifications
Table 118. Roche HeartFailure Drugs Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 119. Roche Main Business
Table 120. Roche Latest Developments
Table 121. Sun Pharma Basic Information, HeartFailure Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Sun Pharma HeartFailure Drugs Product Portfolios and Specifications
Table 123. Sun Pharma HeartFailure Drugs Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 124. Sun Pharma Main Business
Table 125. Sun Pharma Latest Developments
Table 126. Mylan Basic Information, HeartFailure Drugs Manufacturing Base, Sales Area and Its Competitors
Table 127. Mylan HeartFailure Drugs Product Portfolios and Specifications
Table 128. Mylan HeartFailure Drugs Sales (MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 129. Mylan Main Business
Table 130. Mylan Latest Developments



LIST OFFIGURES

Figure 1. Picture of HeartFailure Drugs
Figure 2. HeartFailure Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global HeartFailure Drugs Sales Growth Rate 2020-2031 (MT)
Figure 7. Global HeartFailure Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. HeartFailure Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. HeartFailure Drugs Sales Market Share by Country/Region (2024)
Figure 10. HeartFailure Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of ACEI
Figure 12. Product Picture of Angiotensin II Receptor Blockers
Figure 13. Product Picture of ARNIs
Figure 14. Product Picture of Beta Blockers
Figure 15. Product Picture of Aldosterone Antagonists
Figure 16. Product Picture of Diuretics
Figure 17. Global HeartFailure Drugs Sales Market Share byType in 2025
Figure 18. Global HeartFailure Drugs Revenue Market Share byType (2020-2025)
Figure 19. HeartFailure Drugs Consumed in Reduced EjectionFraction
Figure 20. Global HeartFailure Drugs Market: Reduced EjectionFraction (2020-2025) & (MT)
Figure 21. HeartFailure Drugs Consumed in Preserved EjectionFraction
Figure 22. Global HeartFailure Drugs Market: Preserved EjectionFraction (2020-2025) & (MT)
Figure 23. Global HeartFailure Drugs Sale Market Share by Application (2024)
Figure 24. Global HeartFailure Drugs Revenue Market Share by Application in 2025
Figure 25. HeartFailure Drugs Sales by Company in 2025 (MT)
Figure 26. Global HeartFailure Drugs Sales Market Share by Company in 2025
Figure 27. HeartFailure Drugs Revenue by Company in 2025 ($ millions)
Figure 28. Global HeartFailure Drugs Revenue Market Share by Company in 2025
Figure 29. Global HeartFailure Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global HeartFailure Drugs Revenue Market Share by Geographic Region in 2025
Figure 31. Americas HeartFailure Drugs Sales 2020-2025 (MT)
Figure 32. Americas HeartFailure Drugs Revenue 2020-2025 ($ millions)
Figure 33. APAC HeartFailure Drugs Sales 2020-2025 (MT)
Figure 34. APAC HeartFailure Drugs Revenue 2020-2025 ($ millions)
Figure 35. Europe HeartFailure Drugs Sales 2020-2025 (MT)
Figure 36. Europe HeartFailure Drugs Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa HeartFailure Drugs Sales 2020-2025 (MT)
Figure 38. Middle East & Africa HeartFailure Drugs Revenue 2020-2025 ($ millions)
Figure 39. Americas HeartFailure Drugs Sales Market Share by Country in 2025
Figure 40. Americas HeartFailure Drugs Revenue Market Share by Country (2020-2025)
Figure 41. Americas HeartFailure Drugs Sales Market Share byType (2020-2025)
Figure 42. Americas HeartFailure Drugs Sales Market Share by Application (2020-2025)
Figure 43. United States HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC HeartFailure Drugs Sales Market Share by Region in 2025
Figure 48. APAC HeartFailure Drugs Revenue Market Share by Region (2020-2025)
Figure 49. APAC HeartFailure Drugs Sales Market Share byType (2020-2025)
Figure 50. APAC HeartFailure Drugs Sales Market Share by Application (2020-2025)
Figure 51. China HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. India HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. ChinaTaiwan HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe HeartFailure Drugs Sales Market Share by Country in 2025
Figure 59. Europe HeartFailure Drugs Revenue Market Share by Country (2020-2025)
Figure 60. Europe HeartFailure Drugs Sales Market Share byType (2020-2025)
Figure 61. Europe HeartFailure Drugs Sales Market Share by Application (2020-2025)
Figure 62. Germany HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63.France HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. UK HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa HeartFailure Drugs Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa HeartFailure Drugs Sales Market Share byType (2020-2025)
Figure 69. Middle East & Africa HeartFailure Drugs Sales Market Share by Application (2020-2025)
Figure 70. Egypt HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73.Turkey HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries HeartFailure Drugs Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of HeartFailure Drugs in 2025
Figure 76. Manufacturing Process Analysis of HeartFailure Drugs
Figure 77. Industry Chain Structure of HeartFailure Drugs
Figure 78. Channels of Distribution
Figure 79. Global HeartFailure Drugs Sales MarketForecast by Region (2026-2031)
Figure 80. Global HeartFailure Drugs Revenue Market ShareForecast by Region (2026-2031)
Figure 81. Global HeartFailure Drugs Sales Market ShareForecast byType (2026-2031)
Figure 82. Global HeartFailure Drugs Revenue Market ShareForecast byType (2026-2031)
Figure 83. Global HeartFailure Drugs Sales Market ShareForecast by Application (2026-2031)
Figure 84. Global HeartFailure Drugs Revenue Market ShareForecast by Application (2026-2031)